LP
GMAB icon

LMR Partners’s Genmab GMAB Stock Holding History

LMR Partners’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.16M Buy
+42,196
New +$1.12M ﹤0.01% 1027
2022
Q4 		– Sell
-40,000
Closed -$1.28M – 1177
2022
Q3 		$1.28M Buy
+40,000
New +$1.4M 0.02% 652

Other funds holding GMAB

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

LMR Partners's GMAB Position: Q2 2026 in Review

LMR Partners opened a new position in Genmab (GMAB) in Q2 2026: 42,196 shares worth $1.16M. The stake represents ﹤0.01% of the portfolio and ranks #1027 among its holdings. This is a return to the name: LMR Partners previously reported a position in GMAB as recently as Q3 2022.

LMR Partners first reported a position in GMAB in Q3 2022 and has held it in 2 quarters since. The position peaked at $1.28M in Q3 2022. 292 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

  • LMR Partners held 42,196 shares of Genmab worth $1.16M as of Q2 2026.
  • Genmab was a new LMR Partners position in Q2 2026.
  • Genmab made up ﹤0.01% of LMR Partners's portfolio in Q2 2026, its #1027 holding.
  • LMR Partners first reported a position in Genmab in Q3 2022 and has held it in 2 quarters since.
  • LMR Partners's Genmab position peaked at $1.28M in Q3 2022.
  • 292 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on LMR Partners's 13F filing for Q2 2026, filed 14 Aug 2026.